Saturday 17 October 2026
Export GELS’s income statement to Excel — free account
Gelteq Limited
GELS Healthcare Drug Manufacturers Specialty & Generic
Gelteq Limited’s revenue for fiscal 2025 (year ended June 2025) was $368,500.00, up 282.7% from fiscal 2024.
0.45
0.02
+4.65%
Follow GELS
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to June
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 1.42 | 0.77 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 5.50 | 4.11 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 8 | 8 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.01 | 0.05 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 0 | 0 | 0 | 0 | ||||
| Gross margin, % | — | — | — | — | — | — | 92.12 | 92.10 | 100.00 | 79.73 | |||||
| EBT | — | — | — | — | — | — | (2) | (2) | (2) | (4) | |||||
| EBT margin, % | — | — | — | — | — | — | (565.09) | (565.09) | (2,414.95) | (1,167.87) | |||||
| Net income | — | — | — | — | — | — | 0 | (2) | (2) | (4) | |||||
| Depreciation | — | — | — | — | — | — | — | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.05 | 0.01 | 0.04 | ||||
| Earnings | — | — | — | — | — | — | — | (0.30) | (0.29) | (0.47) | |||||
| Cash flow | — | — | — | — | — | — | — | (0.15) | (0.09) | (0.39) | |||||
| Capex | — | — | — | — | — | — | — | (0.01) | (0.01) | (0.04) | |||||
| Free cash flow | — | — | — | — | — | — | — | (0.16) | (0.10) | (0.43) | |||||
| Book value | — | — | — | — | — | — | 0.00 | 1.58 | 1.22 | 1.10 | |||||
| Shares, m | — | — | — | — | — | — | — | 8 | 8 | 9 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EV/FCF | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | (0.38) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (1) | (1) | (4) | ||||
| Capex | — | — | — | — | — | — | — | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | — | — | — | — | (1) | (1) | (4) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 0 | 0 | (2) | (3) | ||||
| Total debt | — | — | — | — | — | — | 2 | 2 | 3 | 3 | |||||
| Net debt | — | — | — | — | — | — | 1 | 1 | 3 | 3 | |||||
| Shareholders’ equity | — | — | — | — | — | — | 13 | 13 | 10 | 10 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | (15.59) | (15.59) | (16.17) | (31.28) | ||||
| ROIC | — | — | — | — | — | — | (9.35) | (9.35) | (9.73) | (17.46) | |||||
| ROE | — | — | — | — | — | — | 44.10 | (65.48) | (20.70) | (42.72) | |||||
Negative figures in brackets.
Fiscal years to Jun 2025 · fundamentals updated 5 Oct 2026
Charts ten years each
Gelteq Limited vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| INM InMed Pharmaceuticals Inc. | $7.3M | — (loss-making) | — | −26.22% (below 0%: shrinking) | n/m | −40.43% (below 0%: shrinking) | 22.46% | 0.00% | Compare |
| APUS Apimeds Pharmaceuticals US, Inc. | $6.6M | — (loss-making) | — | — | n/m | −67.94% (below 0%: shrinking) | — | 0.00% | Compare |
| SNOA Sonoma Pharmaceuticals, Inc. | $5.5M | — (loss-making) | — (loss-making) | +59.55% (above 0%: growing) | n/m | +69.31% (above 0%: growing) | 40.23% | (0.62%) | Compare |
| GELS Gelteq Limited | $4.6M | — | — | — | — | −40.15% (below 0%: shrinking) | — | — | |
| RDHL Redhill Biopharma Ltd. | $4.4M | — (loss-making) | — (loss-making) | −90.32% (below 0%: shrinking) | n/m | −107.31% (below 0%: shrinking) | (7.52%) | 0.00% | Compare |
| YCBD cbdMD, Inc. | $4.0M | 41.2× | — (loss-making) | +20.55% (above 0%: growing) | n/m | +34.80% (above 0%: growing) | 54.69% | (20.36%) | Compare |
| AKAN Akanda Corp. | $3.5M | — | — | — | — | −472.01% (below 0%: shrinking) | (197.87%) | 0.00% | Compare |
| PRFX PainReform Ltd. | $2.6M | — (loss-making) | — (loss-making) | — | n/m | +52.56% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BTAIQ BioXcel Therapeutics, Inc. | $2.3M | — (loss-making) | — (loss-making) | +51.67% (above 0%: growing) | n/m | +51.51% (above 0%: growing) | 87.91% | (5,600.55%) | Compare |
| Median of peers | $4.2M | — | — | +20.55% | — | −2.82% | 22.46% | 0.00% |
Gelteq Limited (GELS) key facts
- Strength: Gelteq Limited’s revenue for fiscal 2025 (year ended June 2025) was $368,500.00, up 282.7% from fiscal 2024.
- Gelteq Limited (GELS) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, GELS traded at $0.45, a market capitalization of $4.6 million.
- Return on equity was −42.7% and debt-to-equity 0.36.
- Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 0.39 (distress zone) for fiscal 2025.